The US Patent and Trade Office has awarded Aegis Therapeutics US Patent No. 8,268,791 for “Alkylglycoside compositions for drug administration.” The company is highlighting the patent’s coverage of fast-acting intranasal triptan formulations for the treatment of migraine headaches that use Aegis’s Intravail transmucosal absorption enhancers. Aegis says that this is its first patent relating to Intravail formulations of small molecule drugs; it already had a number of patents relating to Intravail formulations of proteins and peptides.
Read the Aegis press release.
View the patent.
